@inproceedings{inproceedings, title  = {{Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis}},

 url = {{}},

 year = {{2022}},

 month = {{1}},

 author = {{Weidinger S and Bieber T and Cork M}},

 volume = {{87}},

 journal = {{JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY}},

 issue = {{3}},

 pages = {{AB123-AB123}},

 note = {{Accessed on 2025/10/26}}}